Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world evaluation of trastuzumab biosimilar (Hanquyou) in HER2-positive cancers
ChiCTR2000035874Phase 4Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab in breast cancer, Gastric cancer (HER2-positive) and cancer, sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Efficacy, Safety and 1 more. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancerGastric cancer (HER2-positive)cancer
Beyond the preview
Go deeper on ChiCTR2000035874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035874.